Mois : mai 2026
-
Ivonescimab with Chemotherapy Demonstrated a Statistically Significant Overall Survival Benefit Compared to Tislelizumab Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
Ivonescimab Plus Chemotherapy Reduced the Risk of Death by 34% Compared to Tislelizumab Plus Chemotherapy; Hazard Ratio 0.66 First Regimen…
Lire la suite » -
Tempus Unveils the Next-Generation of Lens, Expanding its Agentic AI Platform for Oncology Drug Development
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced…
Lire la suite » -
Pfizer’s BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
Cohort 3 analysis from the Phase 3 BREAKWATER study showed a 56% reduction in the risk of disease progression or…
Lire la suite » -
Kelonia Therapeutics Presents Updated First-in-Human Data from Phase 1 inMMyCAR Study of KLN-1010 in vivo BCMA CAR-T Therapy at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
100% ORR and MRD-negative responses observed in all evaluable patients, earliest dosed patients remain in ongoing MRD negative response beyond…
Lire la suite » -
ASCO 2026: Bayer Shares New Findings for NUBEQA® (darolutamide) Regarding Cognitive Decline in Men with Advanced Prostate Cancer Compared to Enzalutamide in Phase II ARACOG Head-to-Head Trial
Phase II ARACOG (AFT-47) head-to-head trial met its primary endpoint, with patients treated with NUBEQA® (darolutamide) showing a decline in…
Lire la suite » -
Salubris Biotherapeutics Announces Updated Phase 1/2 Data for JK06, a 5T4-Targeted Antibody Drug Conjugate, at the 2026 American Society of Clinical Oncology Annual Meeting
Robust enrollment of 173 patients across dose escalation and expansion cohorts, with objective responses observed across five tumor types JK06…
Lire la suite » -
BW LPG Enters Into Agreement for Eight 90’cbm Panamax Newbuildings with Hyundai Heavy Industries
SINGAPORE--(BUSINESS WIRE)--BW LPG Limited (“BW LPG”, the “Company”, OSE ticker code: “BWLPG.OL”), the world’s leading owner and operator of LPG…
Lire la suite » -
Mirum Pharmaceuticals Announces New Data from Rare Liver Disease Programs Presented at the EASL International Liver Congress 2026
- Late-breaking VISTAS results demonstrate rapid, sustained, and clinically meaningful reductions in pruritus with volixibat in primary sclerosing cholangitis (PSC)…
Lire la suite » -
CVLT INVESTOR DEADLINE: Robbins Geller Rudman & Dowd LLP Announces that Commvault Systems, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--$CVLT #CVLT--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Commvault…
Lire la suite » -
INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that Sportradar Group AG (SRAD) Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--$SRAD #SRAD--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Sportradar…
Lire la suite » -
Massive Bio Announces Next-Generation Reticulum Nexus™ Product Suite at ASCO 2026
Sentinel Agents™, NexusPulse™ Intelligent Calculators, DrArturo AI™, Phoebe AI™, Patient Connect™, and TrialRelay™ create a real-time multi-agent orchestration layer for…
Lire la suite » -
Exelixis Announces Results from Subgroup Analysis of Phase 3 CABINET Pivotal Trial Evaluating CABOMETYX® (cabozantinib) in Non-Functional and Functional Neuroendocrine Tumors at ASCO 2026
– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and…
Lire la suite » -
Global Real Assets Trust Reports Q1 2026 Results
TORONTO--(BUSINESS WIRE)--Starlight Investments Capital GP Inc. ("Starlight Capital"), on behalf of Global Real Assets Trust (the "Trust"), announced today the…
Lire la suite » -
Tempus Launches the PRECISION Challenge, a National Program Opening Its Foundation Model Work to the Broader Research Community
Inaugural program provides unprecedented access to Tempus’ library of de-identified multimodal data and models, scalable compute infrastructure and direct funding…
Lire la suite » -
Incyte’s Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi®/Minjuvi®) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
The Phase 3 frontMIND study evaluated tafasitamab (Monjuvi®/Minjuvi®) and lenalidomide in addition to R-CHOP, the current standard of care, compared…
Lire la suite » -
Immunome Announces Detailed Phase 3 RINGSIDE Data for Varegacestat in Adults with Progressing Desmoid Tumors at the 2026 ASCO Annual Meeting
Varegacestat treatment resulted in statistically significant improvements in primary and all key secondary efficacy endpoints Varegacestat demonstrated statistically significant improvement…
Lire la suite » -
Tune Therapeutics Presents Positive Phase 1b/2a Proof of Concept Data on TUNE-401: a First-in-Class Epigenetic Silencer for Patients with Hepatitis B at EASL 2026
Initial clinical data shows deep and durable antiviral activity, including direct silencing of cccDNA, offering a possible pathway to a…
Lire la suite » -
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
First PARP inhibitor + ARPI combination to show consistent rPFS improvement in HRR gene‑altered metastatic hormone‑sensitive prostate cancer, including both…
Lire la suite » -
Tempus Introduces ‘Preview’: Bridging the Critical Time Gap Between Diagnostic Order and Definitive Results
CHICAGO--(BUSINESS WIRE)--Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine, today announced…
Lire la suite » -
Encouraging Global Phase II Ivonescimab Data in First-Line Metastatic Colorectal Cancer Presented at ASCO 2026
Promising Data Further Support Continued Expansion of Ivonescimab Clinical Development in mCRC Overall Study Population Achieved ORR of 70.8% and…
Lire la suite » -
ENZAMET Trial Shows Veracyte’s Decipher Prostate Test Identifies Which Patients Benefit from Adding Chemotherapy in Metastatic Prostate Cancer
Study provides first Level 1B evidence for genomic-guided decisions on triplet therapy in advanced disease Additional ASCO data reinforce Decipher…
Lire la suite » -
FCPT Announces Agreement to Acquire up to 102 Mission Pet Health Veterinary Properties for $268 Million
MILL VALLEY, Calif.--(BUSINESS WIRE)--Four Corners Property Trust (NYSE:FCPT), a real estate investment trust primarily engaged in the ownership and acquisition…
Lire la suite » -
AVAV INVESTOR NOTICE: Robbins Geller Rudman & Dowd LLP Announces that AeroVironment, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit
SAN DIEGO--(BUSINESS WIRE)--$AVAV #AVAV--The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of AeroVironment,…
Lire la suite » -
Shareholder Notice: Robbins LLP Informs Investors of the Lucid Group, Inc. Class Action
SAN DIEGO--(BUSINESS WIRE)--$LCID #LCID--Robbins LLP informs stockholders that a class action was filed on behalf of all investors who purchased…
Lire la suite » -
Ferrari Films Issues Formal Rebuttal to Forbes Article Mischaracterizing Section 168(k) as "Worthless" for Film Investors
Attorney and Producer Challenges Critical Legal Oversights in Forbes Analysis of Federal Film Tax ProvisionsLOS ANGELES--(BUSINESS WIRE)--#168rules--Ferrari Films founder, attorney,…
Lire la suite » -
YSS INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving York Space Systems Inc.
NEW YORK--(BUSINESS WIRE)--The law firm of Kirby McInerney LLP continues its investigation on behalf of York Space Systems Inc. (“York…
Lire la suite » -
Tanner Introduces New AI Voice Chat Assistant to Reduce Call Center Hold Times
The new voice chat AI assistant, Clara, provides 24/7 bilingual support to streamline inbound calls, handle common questions and reduce…
Lire la suite » -
KBRA Assigns AA+ Rating to State of Illinois, Build Illinois Bonds (Sales Tax Revenue), Junior Obligation Series A and B of June 2026; Affirms Parity Debt; Stable Outlook
NEW YORK--(BUSINESS WIRE)--#creditratingagency--KBRA assigns a long-term rating of AA+ with a Stable Outlook to the State of Illinois (the "State"),…
Lire la suite » -
Syncora Guarantee Inc. Announces the Availability of Certain Financial Information
NEW YORK--(BUSINESS WIRE)--Syncora Guarantee Inc. (“Syncora Guarantee”) today announced that certain financial information of Syncora Guarantee has been made available…
Lire la suite » -
Republic Technologies Inc. Provides Bi-Weekly Update On Annual Filings
VANCOUVER, British Columbia--(BUSINESS WIRE)--$DOCKF #Blockchain--Republic Technologies Inc. (CSE: DOCT) (FSE: 7FM0) (OTCQB: DOCKF) (“Republic” or the "Company") today provided an…
Lire la suite »